JHL Biotech Australia

JHL Biotech Australia is the Australian subsidiary of Eden Biologics (formerly JHL Biotech), a biopharmaceutical company specializing in the development of high-quality biosimilars. The company focuses on monoclonal antibodies and other complex biologics, utilizing a proprietary platform to improve the affordability and accessibility of life-changing medicines. JHL Biotech Australia plays a central role in the group's clinical development strategy, particularly in managing Phase 1 and Phase 3 trials for its lead biosimilar candidates in the Asia-Pacific region. Following a corporate rebranding in 2021 and the divestment of its CDMO business to Bora Pharmaceuticals in 2022, the company has focused its resources on advancing its core pipeline. Its most advanced program is EB1001, a denosumab biosimilar currently in Phase 3 clinical trials for osteoporosis. The company is headquartered in Sydney and operates in close collaboration with its parent organization's R&D facilities in Taiwan.